HARBIN, China, Dec. 19, 2011 /PRNewswire-Asia/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ:
CSKI), a leading fully integrated pharmaceutical company in
the People's Republic of China
("PRC"), today announced that Mr. Yanqing
Liu, the Company's Chief Executive Officer and Chairman, was
sent to the hospital due to a massive hemorrhage of his intestinal
tract that occurred on December 17th,
2011. Mr. Liu is going to undertake further medical
examination and tests and will receive any necessary treatment. Mr.
Jianping Li, the Company's General
Manager and a Board Director, has been delegated to supervise the
Company's daily operations during Mr. Liu's sick leave.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The
Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and
Technology Company, Harbin First Bio-Engineering Company Limited,
Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang
Pharmaceutical Company, the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major
revenue source. For more information, visit
http://www.cski.com.cn.
Safe Harbor Statement
Certain of the statements made in the press release
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by the use of forward- looking terminology such
as "believe,"
"expect," "may,"
"will," "should,"
"project," "plan,"
"seek," "intend,"
or "anticipate" or the negative
thereof or comparable terminology. Such statements typically
involve risks and uncertainties and may include financial
projections or information regarding the
Company's daily operation.
Actual results could differ materially from the expectations
reflected in such forward-looking statements as a result of a
variety of factors, including the risks associated with the effect
of changing economic conditions in The People's
Republic of China, variations in
cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks
associated with rapid technological change, the potential of
introduced or undetected flaws and defects in products,
consumer acceptance of new products to be launched and other
risk factors detailed in reports filed with the Securities and
Exchange Commission from time to time.
Investor Relations Contact:
China Sky
One
Medical
|
CCG Investor
Relations
|
|
Hongyu Pan, CFO
|
David Rudnick
|
|
Email: ir@cski.com.cn
|
Tel:
+1-646-626-4172
|
|
|
Email:
david.rudnick@ccgir.com
|
|
|
Website:
www.ccgirasia.com
|
|
|
|
|
|
Mabel Zhang, Vice
President
|
|
|
Tel:
+1-310-954-1353
|
|
|
Email: mabel.zhang@ccgir.com
|
|
|
|
SOURCE China Sky One Medical, Inc.